| | r-axSpA patients (n = 30) | Healthy Donors (n = 32) | P |
|---|
| Clinical parameters |
| Women/men, n/n | 5/25 | 10/22 | 0.180 |
| Age, y | 46.40 ± 2.45 | 41.06 ± 1.77 | 0.080 |
| BASDAI | 4.42 ± 0.45 | … | |
| BASFI | 4.73 ± 0.61 | … | |
| BASMI | 3.22 ± 0.31 | … | |
| mSASSS | 19.16 ± 3.86 | … | |
| Disease duration, y | 13.23 ± 2.07 | … | |
| Extra-articular manifestations |
| ➣ Uveitis | 0/30 | 0/32 | |
| ➣ Psoriasis | 0/30 | 0/32 | |
| ➣ IBD | 0/30 | 0/32 | |
| Laboratory parameters |
| HLA-B27 (%) | 26/30 (86.67%) | … | |
| CRP†, nmol/L | 122.57 ± 31.38 | 13.62 ± 3.25 | < 0.001 |
| ESR†, mm/h | 19.84 ± 4.09 | 7.48 ± 1.00 | 0.006 |
| TNF-α, pg/mL | 10.89 ± 1.82 | 4.02 ± 1.20 | 0.021 |
| IL-1β, pg/mL | 2.46 ± 0.22 | 1.57 ± 0.27 | 0.047 |
| Treatments |
| NSAIDs (%) | 28/30 (93.33%) | … | |
| Sulfasalazine (%) | 2/30 (6.67%) | … | |
- Values are presented as mean ± SEM. The data were analyzed using an Independent Samples t test or a Mann-Whitney U test to evaluate statistical significance between r-axSpA patients and healthy donors. †Non-normally distributed data. BASDAI indicates Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functionality Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HLA, human leukocyte antigen; IBD, inflammatory bowel disease; IL, interleukin; mSASSS, modified Stoke Ankylosing Spondylitis Spine Score; NSAIDs, non-steroidal anti-inflammatory drugs; r-axSpA, radiographic axial spondyloarthritis; TNF, tumor necrosis factor
